Jefferies Downgrades ResMed (RMD) to Underperform; AirSense10 Cycle Waning
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Jefferies downgraded ResMed (NYSE: RMD) from Hold to Underperform with a price target of $58.00 (from $60.00), saying the AirSense10 Cycle is waning.
Analyst Anthony Petrone commented, "We conducted a DME survey and several expert calls to gauge the latest CPAP trends. AirSense10 is still considered best-in-class, but Dream has closed the gap while being priced at a discount. Lower Medicare rates effective July 1, 2016 are pressuring private rates and are expected to lead to further DME consolidation and price pressure. Downgrading to UP as cycles evolve."
Shares of ResMed closed at $69.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- Jefferies Cuts Price Target on Masco Corp. (MAS) to $39
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Downgrades
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!